Vaxart Inc
NASDAQ:VXRT
Vaxart Inc
NASDAQ:VXRT
Price:
0.7837
USD
-1.99%
Market Cap:
$188.1m
Relative Value
The Relative Value of one
VXRT
stock under the Base Case scenario is
1.5573
USD.
Compared to the current market price of 0.7837 USD,
Vaxart Inc
is
Undervalued by 50%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VXRT
Relative Value
Base Case
1.5573
USD
Undervaluation 50%
Multiples Across Competitors
VXRT Competitors Multiples
Vaxart Inc Competitors
Vaxart Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Vaxart Inc
NASDAQ:VXRT
|
175.7m USD | 3.7 | -3 | -2.8 | -2.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.4B USD | 6.6 | 95.8 | 15.7 | 21.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.8B USD | 5.5 | 26.3 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
127.1B USD | 10.5 | 31.9 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.4B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39B EUR | 11.1 | 35.7 | 38.8 | 39.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
